Jiang Cailing, Liu Yulan, Mo Yunyan, Xu Lieyin, Zhu Lin, Li Zhenya, Xu Shengyuan, Qin Xi, Wu Guangteng, Kang Mafei, He Xiaosong, Xue Feng
Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China.
Department of Radiotherapy, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China.
Front Oncol. 2025 Feb 24;15:1504658. doi: 10.3389/fonc.2025.1504658. eCollection 2025.
Treatment of hypopharyngeal carcinoma involves surgery, radiotherapy, and chemotherapy. The combination of docetaxel, cisplatin, and 5-fluorouracil as a standard induction chemotherapy regimen allows enhanced laryngeal preservation after surgery. In this study, our objective was to retrospectively analyze the short-term efficacy and adverse events of nab-paclitaxel plus cisplatin or nedaplatin plus tegafur/gimeracil/oteracil as an induction chemotherapy regimen for hypopharyngeal cancer.
This retrospective study involved 19 patients who received nab-paclitaxel plus cisplatin/nedaplatin plus tegafur/gimeracil/oteracil every 21 days intervals for three cycles at the Affiliated Hospital of Guilin Medical University (December 2020 to February 2023). The primary endpoint was progression-free survival. Adverse events were assessed in all patients.
Treatment response was evaluated after the second cycle. Clinical outcomes indicated that 2 (10.53%), 15 (78.94%), and 2 (10.53%) patients exhibited clinical complete response, partial response, and stable disease, respectively. The objective response and disease control rates were 89.47% (17/19) and 100%, respectively. The pathological complete response rate was 71.43% (5/7) among the seven patients who underwent surgery after three cycles. Following induction chemotherapy, 4 (21.05%), 2 (10.53%), and 2 (10.53%) patients received radiotherapy, chemotherapy, and chemotherapy plus immunotherapy, respectively, whereas 4 (21.05%) patients discontinued treatment. At the 17.43-month median follow-up, median progression-free survival was 17.6 months (95% confidence interval, 13.9-21.2). The most common grade 3 treatment-related adverse events were alopecia (36.8%), leukopenia (26.3%), and anemia (15.8%). No grade 4/5 treatment-emergent adverse events were observed.
The combination of nab-paclitaxel, cisplatin/nedaplatin, and tegafur/gimeracil/oteracil is a safe induction chemotherapy for treating hypopharyngeal cancer.
下咽癌的治疗包括手术、放疗和化疗。多西他赛、顺铂和5-氟尿嘧啶联合作为标准诱导化疗方案可提高术后喉保留率。在本研究中，我们的目的是回顾性分析纳米紫杉醇联合顺铂或奈达铂联合替吉奥作为下咽癌诱导化疗方案的短期疗效和不良事件。
这项回顾性研究纳入了19例在桂林医学院附属医院（2020年12月至2023年2月）每21天接受纳米紫杉醇联合顺铂/奈达铂联合替吉奥治疗三个周期的患者。主要终点是无进展生存期。对所有患者评估不良事件。
在第二个周期后评估治疗反应。临床结果显示，2例（10.53%）、15例（78.94%）和2例（10.53%）患者分别表现出临床完全缓解、部分缓解和疾病稳定。客观缓解率和疾病控制率分别为89.47%（17/19）和100%。在三个周期后接受手术的7例患者中，病理完全缓解率为71.43%（5/7）。诱导化疗后，分别有4例（21.05%）、2例（10.53%）和2例（10.53%）患者接受了放疗、化疗和化疗加免疫治疗，而4例（21.05%）患者停止治疗。在17.43个月的中位随访期，中位无进展生存期为17.6个月（95%置信区间，13.9 - 21.2）。最常见的3级治疗相关不良事件是脱发（36.8%）、白细胞减少（26.3%）和贫血（15.8%）。未观察到4/5级治疗突发不良事件。
纳米紫杉醇、顺铂/奈达铂和替吉奥联合是一种治疗下咽癌的安全诱导化疗方案。
